Incyte INCY
Incyte Q3 FY24: revenue $1.1B; diluted EPS $0.54
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0000879169-24-000172
Key figures from this report
These are the numbers Incyte reported for Q3 FY24, the quarter ended Sep 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$1.1BNo year-earlier figure tagged10-Q income statement, on EDGAR
- Net income$106.5MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Diluted EPS$0.54No year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$1.3BNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations$310.9MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 8731 and related industry codes: the same peer list as the financial tables.
- Charles River Laboratories International CRL public float $7.3B, Jun 28, 2025
- Medpace Holdings MEDP public float $7.0B, Jun 30, 2025
- Iqvia Holdings IQV public float $26.5B, Jun 30, 2025
- UL Solutions ULS public float $4.5B, Jun 30, 2025
